Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 8 years, the highest FCF Margin % of Global Longlife Hospital & Research was 2121.65%. The lowest was -180.50%. And the median was 14.48%.
BOM:543520's FCF Margin % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 3.025 * Ranked among companies with meaningful FCF Margin % only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Longlife Hospital & Research FCF Margin % Chart
BOM:543520 vs HCA, THC, DVA: FCF Margin % Comparison
For the Medical Care Facilities subindustry, Global Longlife Hospital & Research's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Longlife Hospital & Research FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Global Longlife Hospital & Research's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Global Longlife Hospital & Research's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Longlife Hospital & Research (BOM:543520) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Global Longlife Hospital & Research and its competitors. According to the industry distribution chart, Global Longlife Hospital & Research ranks #999999 out of 666 companies in the Healthcare Providers & Services industry.
Is Global Longlife Hospital & Research's FCF Margin % too high?
Global Longlife Hospital & Research's current FCF Margin % is 0.00%. Based on the distribution chart, Global Longlife Hospital & Research ranks #999999 out of 666 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Global Longlife Hospital & Research has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Global Longlife Hospital & Research's FCF Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Global Longlife Hospital & Research ranks #999999 out of 666 companies for FCF Margin %. This places Global Longlife Hospital & Research in the lower half of its industry. The industry median FCF Margin % is 3.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.03, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Global Longlife Hospital & Research and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Global Longlife Hospital & Research's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Longlife Hospital & Research stock overvalued right now?
Based on GuruFocus' analysis, Global Longlife Hospital & Research (BOM:543520) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1.37, compared to a current price of ₹13.04 — trading 851.8% above its estimated fair value. The current FCF Margin % is 0.00%. Global Longlife Hospital & Research's overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Global Longlife Hospital & Research (BOM:543520), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Global Longlife Hospital & Research (BOM:543520) Overvalued in 2026?
Based on GuruFocus' analysis, Global Longlife Hospital & Research stock appears to be overvalued.
The current stock price of ₹13.04 is trading 851.8% above its estimated GF Value™ of ₹1.37.
GuruFocus considers Global Longlife Hospital & Research to be Significantly Overvalued.
Key valuation signals for BOM:543520:
FCF Margin %: 0.00%
GF Value™: ₹1.37 vs. price of ₹13.04 (851.8% above fair value)
No single metric tells the full story. See the BOM:543520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Global Longlife Hospital & Research Ltd is Multispecialty Hospital providing Medical & Allied Services. The company operates in the single segment i.e. Health Care and Hospital. Its services are Medical, Surgical, Radiology, Pathology, and Other Services.
36GF Score
Get the complete analysis for BOM:543520
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543520 has been successfully added to your 
